Physician profile
Aaron Galbraith
NPI 1871835124
$2,572.82
in general payments reported to CMS, 2019-2025
22 companies · $1,776 in 2025
The $1,776 reported for 2025 was more than what 92% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $99.43 · 2023: $244 · 2024: $454 · 2025: $1,776.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,473.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,473.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $366.62 | 2024-2025 | Airsupra, Farxiga |
| Novo Nordisk INC | $348.79 | 2022-2025 | Ozempic, Rybelsus |
| Novartis Pharmaceuticals Corporation | $309.31 | 2022-2025 | |
| Lilly USA, LLC | $265.97 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $194.77 | 2025 | |
| Pfizer INC. | $140.11 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $134.19 | 2023-2025 | Jardiance, Synjardy |
| Glaxosmithkline, LLC. | $107.46 | 2024-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Dexcom, INC. | $97.93 | 2025 | Dexcom G6 Transmitter |
| Exact Sciences Corporation | $91.42 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Astellas Pharma US INC | $79.01 | 2025 | Veozah |
| Aimmune Therapeutics, INC. | $78.12 | 2025 | Zenpep |
| Bayer Healthcare Pharmaceuticals INC. | $72.18 | 2025 | |
| Sanofi-Aventis U.S. LLC | $67.17 | 2022-2023 | |
| Amgen INC. | $56.61 | 2025 | Repatha, Otezla |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $51.65 | 2024-2025 | Rexulti |
| Genzyme Corporation | $24.15 | 2025 | |
| Ultragenyx Pharmaceutical INC. | $22.73 | 2023 | Crysvita |
| Abbott Laboratories | $19.40 | 2025 | Freestyle Libre 3 |
| Acadia Pharmaceuticals INC | $16.61 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $15.81 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12.81 | 2023 | Xifaxan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aaron Galbraith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.